Evidence map›Paper›PMID 39998054›Full record

ArticleTropical medicine and infectious disease2025

Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease.

Ana Lia Mazzeti, Karolina Ribeiro Gonçalves, Patrícia Ferreira Boasquivis, Maria Terezinha Bahia, Vanessa Carla Furtado Mosqueira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine and infectious disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Lia MazzetiLaboratório Integrado de Imunoparasitologia e Farmacotoxicologia, Universidade do Estado de Minas Gerais, Unidade Acadêmica de Passos, Passos 37900-106, MG, Brazil.ORCID 0000-0003-1642-306X
Karolina Ribeiro GonçalvesLaboratório de Doenças Parasitárias, Escola de Medicina & Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil.
Patrícia Ferreira BoasquivisDiretoria Industrial, Fundação Ezequiel Dias, Belo Horizonte 30510-010, MG, Brazil.
Maria Terezinha BahiaLaboratório de Doenças Parasitárias, Escola de Medicina & Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil.
Vanessa Carla Furtado MosqueiraLaboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.ORCID 0000-0002-0368-6090

Funding

FAPEMIG grants APQ-02576-18NANOBIOMG Network #00007-14 and #40/11National Council for Scientific and Technological Development (CNPq) #313602/2019-0Universidade do Estado de Minas Gerais PQ/UEMG 06/2023WHO-A0790 re-entry grant WHO-A0790
6 · The paper itself

Abstract

Chagas disease, caused by

Indexed as

implantsnifurtimoxpoly(ε-caprolactone)self-emulsifying drug delivery systemstrypanosomiasis

Identifiers

PMID39998054
PMCPMC11860281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.